+613 8892 4854
info@immuron.com
:
+613 8892 4854
info@immuron.com
Cart
-
0
Menu
Shop
Cart (
0
)
Account
About Us
About Us
Board of Directors
Management Team
Research Partners
Technology
Technology Platform
Product Pipeline
Intellectual Property
Production
Clinical Insights
Commercial products
In vitro studies into SARS-CoV-2 and IMM-124E
Travelan US Army results
Knowledge Centre
Platform Science
Product Science
Investor Centre
Company Media
Analysts Reports
Corporate Presentations
Company Securities Exchange Announcements
Capital Structure & Register
Corporate Directory and Governance
Corporate Contacts
Contact Us
Products
Travelan®
Protectyn®
About Us
About Us
Board of Directors
Management Team
Research Partners
Technology
Technology Platform
Product Pipeline
Intellectual Property
Production
Clinical Insights
Commercial products
In vitro studies into SARS-CoV-2 and IMM-124E
Travelan US Army results
Knowledge Centre
Platform Science
Product Science
Investor Centre
Company Media
Analysts Reports
Corporate Presentations
Company Securities Exchange Announcements
Capital Structure & Register
Corporate Directory and Governance
Corporate Contacts
Contact Us
Travelan®
Protectyn®
Filter Categories
Media
Investors & Corporate
Pharmaceuticals
Research & Development
Home
Company Media
Investors & Corporate
2017
2017
Filter by Year:
2021
2020
2019
2018
2017
asdasd
6 December 2021
2017 Bioshares Biotech Summit coverage - IMM-124E targets the gut and the microbiome (Bioshares)
26 July 2017
Immuron to start search for partner or buyer of fatty liver therapeutics in Q1 2017
16 January 2016
1